The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.
A subcutaneous injection that can administer an immunotherapy in 1–2 minutes using domestic technology has been developed and approved in the United States. Immunotherapies are usually given ...
Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...
The Chosun Ilbo on MSN
Keytruda Subcutaneous Injection Receives FDA Approval
The first immune checkpoint inhibitor that can be administered via a subcutaneous injection in just 1 to 2 minutes has ...
Leqembi Iqlik's subcutaneous injection for Alzheimer's disease received FDA approval, based on Phase III trial data showing comparable efficacy to IV dosing. The subcutaneous formulation demonstrated ...
For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
SurvivorNet on MSN
FDA Approves New Subcutaneous (Under-the-Skin) Option for Keytruda: What It Means for Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved the subcutaneous form of Keytruda for a new 'Under-the-Skin' Option ...
Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s ...
While the test was conducted in NSCLC, the FDA approval includes existing solid tumor indications for Keytruda. Merck is ...
The FDA has cleared the new version for across most of the solid tumour indications already granted for Keytruda, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback